A New Personalized Risk-Stratification Model for Myelodysplastic Syndromes
Dr. Nazha discusses a new tool for the risk-stratification of patients with myelodysplastic syndromes, which outperformed traditional risk models.
Dan T. Vogl, MD: Selinexor Plus Low-Dose Dexamethasone in “Penta-Refractory” Myeloma Patients
Heavily-refractory myeloma patients who have exhausted available treatment agents were able to achieve a response with the investigational agent selinexor. Dr. Vogl shares results...
Age, Comorbidity, Time on Chemotherapy Predict Increases in Hospitalizations, ER Visits Among CLL Patients
Researchers identified several risk factors leading to greater health-care resource use, including age, comorbidity burden, presence of adverse events, and duration of therapy, in...
Current Issue
February 2020, Volume 6, Issue 3
This issue examines the high price of treating hemophilia, asks whether CAR T-cell therapies are worth the cost, and more.
